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Where it 
all began
September 2008
Beyond 4.5 Hours? 
May 2012
No diff in 6 months outcomes… NEGATIVE TRIAL
February 2016
MR WITNESS
• 80 subjects – DWI positive, FLAIR negative
• 71% symptoms discovered at wake-up
• 59% white, 54% male, mean age 67
• 14% had pre-stroke mRS >1
• Median NIHSS 7.5 (IQR 4.3-13.8)
• Results: tPA treatment started at median of 11.3
hr from LSW
• Time from discovery to tPA: 3.85 hr (2.83-4.25)
• Only 1 in 80 patients had sICH for a rate of 1.25%
Wake-Up
August 
2018
• 503 patients randomized
• median interval between the time that the 
patient was last known to be well and 
treatment initiation was 10.3 hours 
Efficacy and safety of MRI based thrombolysis 
in wakeup stroke: RANDOMIZED, DOUBLE 
BLIND, PLACEBO CONTROLLED
mRS 0-1
Protocol at HFH as of October 2018
Half-life 20–24 minutes
Circulating 
fibrinogen
4–15% decrease
Clearance Liver
Indication AMI
Administration
Single weight-based 
bolus of   30-50 mg
Tenecteplase Structure and Pharmacokinetics
Reprinted from Nordt TK, Bode C. Heart 2003;89:1358-1362. © 2003, BMJ Publishing Group Ltd.
AMI=acute myocardial infarction; EGF=epidermal growth factor.
TNKase® (tenecteplase) prescribing information.
Tenecteplase is a 
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TNK vs. placebo 4.5-24 hours from last known well 
Randomized trial, expected 
study completion next year
TIMELESS – PHASE III trial
Ongoing since March 2019
Tenecteplase for acute stroke with LVO
4.5-24 hour time window
Post tPA intracranial hemorrhage

Strategies to extend tPA time window
• BBB stabilizers – reduce tPA
related ICH
Studied in humans
Studied in Animals

